Remove 2019 Remove Prescription Remove Sales
article thumbnail

Biden proposes subsidizing drug middlemen for insulin

World of DTC Marketing

Under the bill proposed, Medicare beneficiaries and those insured through private plans would pay no more than $35 for a 30-day insulin prescription, or the lesser of $35 or 25% of the plan’s negotiated price for a 30-day prescription. This could cost taxpayers billions over the year. Los Angeles Times. billion to $5.7

Insurance 240
article thumbnail

The fairytale of DTC TV ads

World of DTC Marketing

Using the same ads to advertise prescription drugs repeatedly is a waste of money and doesn’t lead to sales. According to a 2019 study from Kantar , a whopping 70 percent of consumers say they see the same ads over and over again. ” Ninety-two percent of U.S. Nowhere is this clearer than in pharma DTC TV ads.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New FDA head needs to examine the accelerated approval program

World of DTC Marketing

The analysis focused on Medicare Part B and Part D spending — which covers outpatient medical care and prescription drugs, respectively, — in 2017, 2018 and 2019, the researchers said. That money is gone without any clinical benefit and the executives at those drug companies received compensation because of those sales.

FDA 234
article thumbnail

Pharma is “big business” that uses excuses to keep prices high

World of DTC Marketing

Seventy-nine percent of Americans think the price of prescription drugs is “unreasonable,” according to a 2019 Kaiser Family Foundation poll , and about 9 in 10 say they support the idea of the government negotiating prices. sales of the 20 top-selling drugs worldwide totaled $101.1 Washington Post. In other words, the U.S.

Pharma 241
article thumbnail

Novartis said to be eyeing sale of ophthalmology, respiratory units

pharmaphorum

Novartis has already spun out its eyecare business Alcon, and is now considering the sale of its ophthalmology and respiratory medicines businesses as it continues a narrowing of its focus, according to media reports. Meanwhile, Lucentis sales have been in decline as a result of biosimilar competition, contracting 11% to $1.55

Sales 125
article thumbnail

What Pear Therapeutics’ Bankruptcy Has Left the DTX Industry to Ponder

MedCity News

Bringing the very first prescription digital therapeutic (PDT) to market in 2017, Pear Therapeutics went above and beyond to follow suggested regulatory guidelines, obtained Food & Drug Administration (FDA) clearance, and provided solid clinical study evidence. Photo: Bulat Silvia, Getty Images

article thumbnail

Insulin prices demonstrate pharma’s greed

World of DTC Marketing

According to the Mayo Clinic “The 3 main reasons cited by pharmaceutical companies for the high cost of new prescription drugs do not apply to insulin. 9 One vial of Humalog (insulin lispro), which used to cost $21 in 1999, costs $332 in 2019, reflecting a price increase of more than 1000%. .